SCHEMBL7142633

SCHEMBL7142633

Nc1nc(NCCc2ccccc2)c([N+](=O)[O-])c(-c2ccco2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 11/20 0.63
ADORA1 P30542 10/20 0.63
KMT2A Q03164 2/20 0.52
APP P05067 1/20 0.46
LMNA P02545 2/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 4/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
STAT6 P42226 1/20 0.44
HIF1A Q16665 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 2/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADORA2B P29275 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5044569 0.94 ADORA2A (0.61) ADORA2AADORA1KMT2AMAPTTDP1
SCHEMBL7146124 0.91 ADORA2A (0.57) ADORA2AADORA1KMT2AALDH1A1ADORA3
SCHEMBL7149785 0.89 ADORA2A (0.66) ADORA2AADORA1KMT2ALMNAMAPT
SCHEMBL7146726 0.88 ADORA2A (0.64) ADORA2AADORA1KMT2AMAPTTDP1
SCHEMBL7145041 0.88 ADORA2A (0.56) ADORA2AADORA1MAPTKDM4EALDH1A1
SCHEMBL7153408 0.86 ADORA2A (0.61) ADORA2AADORA1KMT2AAPPTP53
SCHEMBL7403881 0.84 ADORA2A (0.59) ADORA2AADORA1KMT2AMAPTKDM4E
SCHEMBL7145305 0.83 ADORA2A (0.63) ADORA2AADORA1KMT2AMAPTTDP1
SCHEMBL7148045 0.83 ADORA2A (0.61) ADORA2AADORA1KMT2AMAPTTDP1
SCHEMBL7146934 0.81 APP (0.51) ADORA2AADORA1APPLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885KMT2A 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.